The biopharma industry’s fate lies largely in its R&D successes and failures. Here, Scrip looks at five clinical trial successes that will shape their sponsors’ futures and got readers clicking in 2023.
Sanofi and Regeneron Pharmaceuticals, Inc. are now well positioned to add a new blockbuster-sized indication to the labelling for their behemoth anti-inflammatory Dupixent (dupilumab), namely chronic obstructive pulmonary disease (COPD), following successful readouts for two identical Phase III trials this year.
The first of these, BOREAS, in March confounded skepticism surrounding the usefulness of biologics in this challenging respiratory condition in...
INFOGRAPHIC: Deal volume for both M&A and alliances fell in 2023, but average valuations rose appreciably. Antibody-drug conjugates for cancer drove high-value acquisitions and partnerships.
A rundown of the ten most valuable drug launches expected in 2024 from both big pharma and some first-to-market companies.
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are ten (plus a few extras) that have caught Scrip’s eye for one reason or another, eg, for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.
As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
